![](https://www.techtarget.com/rms/onlineimages/folder-files02_searchsitetablet_520X173.jpg)
Getty Images
Vivalink's Biometrics Data Platform Monitors Oncology Patients
A clinical trial of 80 oncology patients undergoing outpatient intermediate-risk chemotherapy regimens will leverage Vivalink's biometrics data platform to detect neutropenic fever events.
Digital healthcare solutions company, Vivalink, will provide its Biometric Data Platform to help detect neutropenic fever events in oncology patients.
Vivalink is at the forefront of decentralized clinical trials. The company has successfully deployed its platform in various clinical applications globally since the start of the COVID-19 pandemic.
Now, the UCLA Jonsson Comprehensive Cancer Center will conduct a joint non-randomized study of 80 cancer patients undergoing outpatient intermediate-risk chemotherapy regimens. All patients will use Vivalink's continuous temperature monitor, a clinical-grade wearable thermometer accurate to within 0.1°C.
The monitor will record patients' axillary temperatures every 10 minutes for the first 84 days of each regimen. If providers detect a fever within this time, both patients and their oncologists will be notified in real-time. Patients will then get their blood drawn to confirm neutropenia.
"Vivalink's platform ability to produce accurate, medical-grade data has attracted different applications and uses from pharmaceutical to medical technology companies, demonstrating the immense value and need for this data in the healthcare industry," Jiang Li, CEO of Vivalink, said in the announcement.
Neutropenic fever is a potentially serious complication of cytotoxic chemotherapy and may occur without symptoms or during non-waking hours. Early detection and treatment are vital to manage the condition effectively.
Vivalink's Biometrics Data Platform includes a portfolio of FDA-, CE-, and NPMA-cleared reusable wearable sensors to detect a range of human vitals, including heart rate, respiratory rate, temperature, oxygen saturation, blood pressure, and ECG.
Additionally, the platform includes an FDA- and CE-cleared arrhythmia detection algorithm and cloud data services that are HIPAA and GDPR compliant.
Alacrity Care is a notable organization currently developing monitoring solutions for oncology treatments that connect patients, providers, and caregivers throughout the cancer treatment journey.
Using Vivalink's platform for remote continuous temperature and ECG monitoring, Alacrity Care offers better insights into what is happening throughout the treatment journey and helps to avoid unnecessary hospitalizations due to more proactive care.